A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis

70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Chile, 21 - 27 April 2018, vol.90, (Summary Text)